paroxysmal nocturnal hemoglobinuria (PNH) | Page 21 | Aplastic Anemia & MDS International Foundation Return to top.

paroxysmal nocturnal hemoglobinuria (PNH)

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer
For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines in patients with solid cancers, such as lung, breast, or prostate cancer.
November 2021 – Lung Cancer
Laura Morgan

Winter Patient and Family Virtual Conference, November 13, 2021

Event Date: 
Sat, 11/13/2021 - 8:00am (EST)
Conference Event Type: 

Fall Patient and Family Virtual Conference, September 11, 2021

Sessions

Understanding Low Risk MDS 2021 Fall Patient Family Conference
  Suresh Balasubramian, MD, Karmanos Cancer Center

Understanding Aplastic Anemia 2021 Fall Patient Family Conference
  Daria Babushok, MD, PhD, Penn Medicine

Event Date: 
Sat, 09/11/2021 - 8:00am (EDT)
Conference Event Type: 

Summer Patient and Family Virtual Conference, July 17, 2021

Sessions

Managing the Side Effects of Bone Marrow Failure - Summer 2021 Conference
 Eric Padron, MD, Moffitt Cancer Center

Diagnosing Bone Marrow Failure Diseases - Summer 2021 Conference
 Amy Duffield, MD, PhD, Memorial Sloan Kettering

Event Date: 
Sat, 07/17/2021 - 8:00am (EDT)
Conference Event Type: 

Aplastic Anemia, Myelodysplastic Syndromes, and Myeloproliferative Neoplasms: The 8th (Virtual) Patient Conference, June 26, 2021

Sessions

8th Seattle Patient Conference: Ask an Expert
 H. Joachim Deeg, MD

8th Seattle Patient Conference - Living Well with MDS/MPN
 Krisstina Gowin, DO, University of Arizona

Event Date: 
Sat, 06/26/2021 - 8:00am (EDT)
Conference Event Type: 

Spring Patient and Family Virtual Conference, April 10, 2021

Event Date: 
Sat, 04/10/2021 - 8:00am (EDT)
Conference Event Type: 

Iptacopan (LNP023)

Iptacopan (LNP023) is a first-in-class, orally administered, potent and highly selective factor B inhibitor of the alternative complement pathway. It is currently in clinical development for treating PNH.

Share with addtoany.com.